Chapter 19 Exercises — The Gray Market

Thirty-four items. Work them in order if you are studying the chapter properly; skip to Section F if you want the hard ones. Items marked † are extended: they require you to hold two ideas at once, to argue against your own position, or to bring in material from earlier chapters. There are no answers here — several of these questions have more than one defensible response, and the reasoning is the point.

A reminder about what this chapter forbids, which applies to your answers too. Nothing you write for these exercises should contain a dose, a preparation method, a handling procedure, or the name of a supplier. If an answer you have drafted could be lifted out and followed, you have answered a different question than the one asked.

Section A — Vocabulary and foundations

1. Define release as the term is used in pharmaceutical manufacturing. Your definition must name who performs it, what they compare, and what it creates that did not exist before.

2. Distinguish purity from peptide content in one sentence each. Then explain why a product labeled by gross weight can be honest and still contain less peptide than a buyer expects.

3. In your own words, state the difference between sterility and endotoxin as quality attributes. Then explain why a batch can pass one and fail the other in either direction.

4. What is a deletion sequence, and what feature of solid-phase synthesis produces it? Why is it harder to remove than an unrelated contaminant would be?

5. Define epistemic laundering without using any of the four roles named in §19.2's diagram. Your definition should be general enough to apply to a market other than peptides.

6. Write the sentence that captures the logical form of a certificate of analysis — the one that explains why a CoA cannot by itself establish what is in a specific container.

Section B — The six failure modes

7. For each of the six independent questions in §19.3, name the failure it detects and state, in one clause, what a person would observe if that failure occurred and nobody caught it.

8. Chapter 1 established that oxytocin and vasopressin differ at two of nine positions. Explain how that fact bears on the identity failure mode, and why "it's a closely related peptide" is not a reassuring thing to learn about a vial.

9. § 19.3 argues that a concentration error is not a proportional error in effect. Reconstruct that argument using Chapter 2's account of receptor amplification. Where on a dose–response curve would a twofold content error matter least, and where would it matter most?

10. † Explain why endotoxin survives autoclaving and passes through sterilizing filtration. Then construct the clinical scenario in which an endotoxin reaction would most likely be misattributed, and say what a supervised setting would do differently. Do not describe any procedure.

11. Aggregation is described in the chapter as a seventh problem rather than one of the six. What distinguishes it from the other six, and why does that distinction matter for who is responsible?

12. † The intuitive model of a mishandled peptide is that it lost potency. State the intuitive model precisely, then state the correct model, then explain what practical difference the correction makes to how a person should think about a vial with an uncertain history.

13. Explain, in terms a non-scientist would follow, why anti-drug antibodies that cross-react with an endogenous peptide are a categorically different problem from a drug that stops working.

Section C — Documents, claims, and the market

14. Take the sentence "our product is third-party tested" and list every question it leaves unanswered. Aim for at least six.

15. §19.4 refuses to give a percentage for how often gray-market products fail testing. Give three distinct methodological reasons for that refusal.

16. † A survey of unregulated products reports that most samples contained approximately the right peptide at approximately the labeled content. Write a two-paragraph commentary: the first stating what that survey genuinely establishes, the second stating what a reader would be wrong to conclude from it. Name at least one attribute that was almost certainly not measured.

17. Reconstruct §19.2's laundering diagram from memory, in your own words. Then identify which single link you think is most defensible on its own terms, and explain why its individual defensibility is exactly what makes the chain work.

18. † Write the strongest honest version of the argument that the "research use only" label is mere legal theater — strong enough that someone who believes it would recognize their own position. Then write the response. You may not use the word dangerous in either half.

19. A vendor's page states, accurately, that its material is produced in a facility that also supplies pharmaceutical customers. Write out precisely what that sentence establishes, and precisely what it does not.

Section D — Compounding and supervision

20. State three concrete differences between a 503A pharmacy and a 503B outsourcing facility, and one thing that is true of both.

21. Explain the sentence "a legal supply chain is not an evidentiary claim" to someone who has just been told that their peptide comes from a licensed pharmacy and therefore must work.

22. In the compounded semaglutide episode, two quality concerns arose that had nothing to do with anyone lying. Name both, and for each, state the general lesson that applies beyond semaglutide.

23. † §19.7 lists seven things medical supervision provides. Rank them in the order you think matters most for a person already using an unregulated compound, and defend your top choice against the obvious objection that the person could obtain some version of it themselves.

24. Explain the escalating-dose trap from Chapter 2 §2.8 in your own words, and state exactly why "it's working less well, so I should use more" is a dangerous inference rather than merely a wrong one.

25. † A new symptom appears in someone using a compound. Describe what attribution looks like and what differential diagnosis looks like, and then argue that both directions of attribution error — toward the compound and away from it — can produce serious harm. Give a distinct example of each.

Section E — Reporting, legality, and evidence

26. List the components of a functioning pharmacovigilance system named in §19.8, and for each, state what the gray market has instead.

27. Explain, in three sentences, why "no one has reported problems with this source" is close to uninformative. Your explanation must distinguish between harm not occurring and harm not being collected.

28. † Chapter 3's cadaver growth hormone case is described as the standing precedent for this chapter. Explain what the case demonstrates about detection rather than about growth hormone, and state what would have happened had the same contamination occurred in an undocumented market.

29. Reconstruct §19.9's six legal questions from memory. Then take the statement "it's legal, my doctor prescribes it" and identify which question it answers and which it leaves open.

Section F — Synthesis and transfer

30. † Draw §19.10's two-axis diagram from memory and place four items in it: an approved medicine correctly dispensed; a compounded product from a 503B facility; genuine research-grade material of a compound with no human trials; and a compound with strong trial evidence obtained through an unregulated channel. Defend the placement of the last one, which is the one people argue about.

31. † Write the chapter's closing position — that this is not anti-peptide — as a single paragraph addressed to a specific reader who has already bought something and expects to be criticized. You may not use the words should, must, or just.

32. Chapter 17 rated the popular BPC-157 claims ❌ on the evidence. Explain why that rating and the quality concerns of this chapter are independent findings, and describe a state of the world in which one changed and the other did not.

33. † Compose a 📊 Evidence Rating — all four lines — for the claim "material from a facility that also supplies pharmaceutical customers is pharmaceutical-grade." The fourth line, what would change the rating, is the one that will take you longest and is the one being assessed.

34. † A friend tells you they have been using something obtained online for four months, has felt fine, and asks whether they should bother telling their doctor. Write your reply in under 200 words. It must contain no instruction, no judgment, and at least two specific reasons drawn from §19.7 or §19.8. Then write one sentence on what you deliberately left out, and why.